Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1

Interventions

Cyclophosphamide 6fludarabine 4Standard of Care 4Practice Guidelines as Topic 3Mycophenolic Acid 3GSK2636771 3venetoclax 2trametinib 2talquetamab 2osimertinib 2dabrafenib 2X-Rays 2Whole-Body Irradiation 2Thiotepa 2Tacrolimus 2Specimen Handling 2Mesna 2Melphalan 2Magnetic Resonance Spectroscopy 2Filgrastim 2Biopsy 2ulixertinib 1trastuzumab biosimilar HLX02 1thymoglobulin 1sapanisertib 1ruxolitinib 1relatlimab 1plerixafor 1pertuzumab 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × benralizumab × 30 days × Clear all
NCT04552288 2026-06-01

Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
51 enrolled 8 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡